Clinical Trials Browser

Interventional × Recurrence × Brentuximab Vedotin × Clear all

NCT01909934 2025-09-19

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Phase 4 Completed

50 enrolled 22 charts

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Phase 2 Recruiting

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2/3 Recruiting

Hodgkin Disease, Recurrence

NCT06761911 2025-01-07

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Phase 4 Not yet recruiting

Hodgkin Disease, Recurrence

NCT02388490 2024-09-23

Bretuximab

Phase 2 Completed

25 enrolled 12 charts

Lymphoma, Recurrence

NCT01492088 2024-05-30

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Phase 1/2 Completed

36 enrolled 26 charts

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT02096042 2023-10-10

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

1 enrolled 3 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT03302728 2022-05-19

EpiBrentlen

Phase 1 Completed

DermatologicLymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02429375 2022-05-12

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

7 enrolled 10 charts

Hodgkin Disease, Recurrence

NCT02686346 2021-12-07

BV-ICE

Phase 1/2 Completed

Hodgkin Disease, Recurrence

NCT01990534 2021-04-09

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Phase 4 Completed

60 enrolled 21 charts

Hematologic Diseases, Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03474133 2020-07-21

BASALT

Phase 2 Unknown

Hodgkin Disease, Recurrence

NCT02780011 2018-07-27

AD3LE

Phase 1 Withdrawn

Recurrence

NCT02280993 2018-03-13

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Phase 1 Unknown

Hodgkin Disease, Recurrence

NCT01841021 2017-01-19

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

Phase NA Terminated

1 enrolled 5 charts

Recurrence, Lymphoma, T-Cell, Peripheral

NCT01950364 2016-05-11

A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Phase 1 Completed

20 enrolled 59 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large-Cell, Anaplastic